Kelly Thomas Patrick Insider Trades & Stock Holdings

Chief Financial Officer · Xenon Pharmaceuticals Inc. · Latest filing Sep 30, 2026

Kelly Thomas Patrick, Chief Financial Officer at Xenon Pharmaceuticals Inc. has 1 Form 4 trade on file since Sep 30, 2026. Open-market activity: 1 purchase ($559.74K) and 0 sales ($0), net +$559.74K. Latest filing: acquired 15K shares of $XENE on Sep 30, 2026 at $37.32.

Trades on file

1

Open-market bought

$559.74K

Open-market sold

$0

Net open-market

+$559.74K

Latest filing

Sep 30, 2026

All insider trades by Kelly Thomas Patrick

Date	Ticker	Type	Shares	Price	Value	Owned after	ΔOwn	1W	1M	6M	Role	Filing	Story
Sep 30, 2026	$XENE	Buy (Open-market buy)	15K	$37.32	$559.74K			-2.1%			Chief Financial Officer		—

"Buy" means shares acquired on the Form 4 (including grants and option exercises); "Sell" means shares disposed. 1W / 1M / 6M = how the stock moved after the trade.

Stocks Kelly Thomas Patrick traded

• $XENE

Frequently asked questions

Has Kelly Thomas Patrick been buying or selling stock?

Kelly Thomas Patrick has 1 open-market purchase and 0 open-market sales on file, net +$559.74K. Grants, option exercises and tax withholding are listed separately because they are not open-market trades.

What was Kelly Thomas Patrick's latest insider trade?

acquired 15K shares of $XENE on Sep 30, 2026 at $37.32.

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.